Navigation Links
Harvest Technologies Announces Initial Enrollment in Its REVIVE-1 Trial (REtrograde Vascular Infusion of BMAC to ImproVe Heart FailurE)
Date:4/20/2011

PLYMOUTH, Mass., April 20, 2011 /PRNewswire/ -- Harvest Technologies Corp. (www.harvesttech.com) announced today that the first twelve patients of its sixty patient Heart Failure trial have been enrolled at Medanta-the Medicity in Gurgaon INDIA.

The trial is intended to evaluate the safety and clinical effect of Harvest's BMAC autologous cell composition to treat patients with Congestive Heart Failure (CHF) when using a minimally invasive retrograde coronary sinus delivery.  This is a randomized, controlled design treating both ischemic and non-ischemic heart failure patients.  Patient enrollment will take place in sites in India, Germany and Peru and will feature electronic data entry with its data coordinating center at the University of Utah. The overall trial will be directed by Amit Patel, MD, Director, Center for Cardiac Cell Therapy at the University of Utah. The trial is being conducted in compliance with the United States FDA clinical trial regulations, ICH GCP, local IRB or IEC regulations and the "Declaration of Helsinki" and a Data Safety Monitoring Board (DSMB) will monitor adverse events.  

Congestive Heart Failure is a persistent and relentless problem, which affects over an estimated 20 million patients world-wide. It occurs when the heart's ability to pump blood is so impaired that "systemic perfusion is inadequate to meet the body's demands" and this condition cannot be mediated by either by medication or surgical or endovascular intervention. A major advance in treatment is needed which could reverse this condition and in ischemic patients initiate neovascularization to restore perfusion within the affected area of the myocardium.

While there are several cardiac trials that have shown a clinical effect arising from the delivery of bone marrow cells through the coronaries, this approach offers several advantages according to Dr. Patel. "This novel delivery approach has several advantages over the antigrade approach. It is a safer approach into the heart, allows for the delivery of significantly more cells and in our experience results in substantially greater cell retention. In addition, the Harvest rapid processing of bone marrow in the procedure room could allow the procedure to be done on an outpatient basis."

"Congestive Heart Failure is a cruel, debilitating disease effecting over 20 million people. Although many of the cell therapy studies have demonstrated promise, the improvements shown have been less than ideal. We are extremely optimistic that this study will show the improvement in clinical results that can eventually lead to a treatment option for this patient population," states Gary Tureski, President Harvest Technologies.

Harvest Technologies is a privately held company based in Plymouth, Mass.

Contact:

P. Kevin Benoit; VP / General Manager Strategic Business Development – 508-732-7500


'/>"/>
SOURCE Harvest Technologies Corp.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Nanonets give rust a boost as agent in water splittings hydrogen harvest
2. Scientists produce transparent, light-harvesting material
3. Gloabl Harvest Initiative: Taking Down Fences To Meet Future Needs
4. Harvest Technologies Announces Trial Results in its India Study Using BMAC to Treat Patients With Non-Reconstructable Critical Limb Ischemia
5. Harvest Technologies Announces Completion of Patient Enrollment in its Randomized, Controlled, Double Blind Multicenter IDE Non-Reconstructable Critical Limb Ischemia Trial
6. UK scientists developing intelligent harvesting robot to save farms up to 100,000 a year
7. Harvest Technologies Announces Completion of Patient Enrollment in its 60 Patient Clinical Trial in India Using Autologous Adult Stem Cells to Treat Patients With Non-Reconstructable Critical Limb Ischemia
8. Scientists determine the structure of highly efficient light-harvesting molecules in green bacteria
9. Mach One Corporation Completes Acquisition of Ceres Organic Harvest, Inc.
10. Mach One Corporation Signs Definitive Agreement to Acquire Ceres Organic Harvest, Inc.
11. Life Technologies to Present at Bairds 2011 Growth Stock Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... 27, 2016  Liquid Biotech USA ... of a Sponsored Research Agreement with The University ... (CTCs) from cancer patients.  The funding will be ... correlate with clinical outcomes in cancer patients undergoing ... then be employed to support the design of ...
(Date:6/24/2016)... ... June 24, 2016 , ... While the majority of ... the Cary 5000 and the 6000i models are higher end machines that use the ... of the spectrophotometer’s light beam from the bottom of the cuvette holder. , ...
(Date:6/23/2016)...   Boston Biomedical , an industry leader ... target cancer stemness pathways, announced that its lead ... Designation from the U.S. Food and Drug Administration ... gastroesophageal junction (GEJ) cancer. Napabucasin is an orally ... stemness pathways by targeting STAT3, and is currently ...
(Date:6/23/2016)... ... 23, 2016 , ... Charm Sciences, Inc. is pleased to ... AOAC Research Institute approval 061601. , “This is another AOAC-RI approval of the ... Vice President of Regulatory and Industrial Affairs. “The Peel Plate methods perform comparably ...
Breaking Biology Technology:
(Date:5/24/2016)... 24, 2016 Ampronix facilitates superior patient care by providing unparalleled technology to ... display is the latest premium product recently added to the range of products distributed ... ... ... Imaging- LCD Medical Display- Ampronix News ...
(Date:5/12/2016)... -- WearablesResearch.com , a brand of Troubadour Research ... the Q1 wave of its quarterly wearables survey. A ... to a program where they would receive discounts for ... "We were surprised to see that so ... , CEO of Troubadour Research, "primarily because there are ...
(Date:4/28/2016)... BANGALORE, India , April 28, 2016 /PRNewswire/ ... product subsidiary of Infosys (NYSE: INFY ), and ... global partnership that will provide end customers with ... banking and payment services.      (Logo: http://photos.prnewswire.com/prnh/20130122/589162 ... area for financial services, but it also plays a fundamental ...
Breaking Biology News(10 mins):